These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27145494)

  • 1. A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6.
    Tian W; Wang L; Yuan L; Duan W; Zhao W; Wang S; Zhang Q
    Cancer Sci; 2016 Jul; 107(7):882-9. PubMed ID: 27145494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
    Qian XL; Xu P; Zhang YQ; Song YM; Li YQ; Li WD; Jiang CY; Shen BB; Zhang XM; Zhang LN; Fu L; Guo XJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):311-319. PubMed ID: 31993861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
    Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
    J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
    Yeong J; Lim JCT; Lee B; Li H; Chia N; Ong CCH; Lye WK; Putti TC; Dent R; Lim E; Thike AA; Tan PH; Iqbal J
    Front Immunol; 2018; 9():1209. PubMed ID: 29899747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
    Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
    J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.
    Wang K; Li HL; Xiong YF; Shi Y; Li ZY; Li J; Zhang X; Li HY
    Cancer Med; 2019 Feb; 8(2):686-700. PubMed ID: 30677255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
    Houvenaeghel G; Sabatier R; Reyal F; Classe JM; Giard S; Charitansky H; Rouzier R; Faure C; Garbay JR; Daraï E; Hudry D; Gimbergues P; Villet R; Lambaudie E
    Br J Cancer; 2016 Oct; 115(9):1024-1031. PubMed ID: 27685443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
    Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
    Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer.
    Zhou Q; Xu J; Xu Y; Sun S; Chen J
    Front Immunol; 2023; 14():1176647. PubMed ID: 37671167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
    Stovgaard ES; Nielsen D; Hogdall E; Balslev E
    Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
    Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
    J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD163
    Omilian AR; Cannioto R; Mendicino L; Stein L; Bshara W; Qin B; Bandera EV; Zeinomar N; Abrams SI; Hong CC; Yao S; Khoury T; Ambrosone CB
    Breast Cancer Res; 2024 May; 26(1):75. PubMed ID: 38720366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of prognostic factors related to triple-negative breast cancer].
    Shen SJ; Sun Q; Zhou YD; Guan JH; Mao F; Lin Y; Peng L; Xu Y; Wang XF; Xia W; Yao R; Han SM
    Zhonghua Wai Ke Za Zhi; 2013 Nov; 51(11):1000-4. PubMed ID: 24444685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.